Thu, Dec 25, 2014, 6:50 AM EST - U.S. Markets closed for Christmas

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

rehdvm2004 145 posts  |  Last Activity: 21 hours ago Member since: Oct 21, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • rehdvm2004 rehdvm2004 Dec 18, 2014 1:03 PM Flag

    You are not understanding that it is not likely a preventive vaccination. Cancer is not like Ebola. Cancers mutate all the time which is why you have to treat with multiple methods.

    Sentiment: Strong Buy

  • Reply to

    I have many questions re: today's PR

    by alexp1112 Dec 18, 2014 9:23 AM
    rehdvm2004 rehdvm2004 Dec 18, 2014 1:01 PM Flag

    Patient enrollment is based upon inclusion and exclusion criteria. Each has an important part. For a Phase I/Phase IIa (single dose and increasing dose safety) you need patients that can endure the sensations associated with administration of the immunotherapy and (hopefully) ones with enough reserves to respond and survive beyond what would otherwise be expected from historic controls.

    GLTAL

    PS - Good thread. It appears that several clinical scientists are in discussion.

    Sentiment: Strong Buy

  • Reply to

    I have many questions re: today's PR

    by alexp1112 Dec 18, 2014 9:23 AM
    rehdvm2004 rehdvm2004 Dec 18, 2014 12:56 PM Flag

    If a significantly debilitated patient can take the regimen, then an early diagnosed patient is in a much better situation for not only safety, but an optimum chance for efficacy.

    Sentiment: Strong Buy

  • Reply to

    I have many questions re: today's PR

    by alexp1112 Dec 18, 2014 9:23 AM
    rehdvm2004 rehdvm2004 Dec 18, 2014 12:18 PM Flag

    So the collaboration between Inovio and UPenn takes precedent over any partnership with BP. They need to get results first, then start looking for a partner for manufacturing. Remember INO has only pilot capability for manufacturing. Fortunately for fermented molecules, one multi liter fermenter with step down filters, chromatography columns, etc. can fit on a 4X4 palate. But if you are going to make millions of doses, you need a CMO for scale up or a BP partner. UPenn is only the clinical site and probably the source of the tumor antigens or other immunogenic molecules that have been "spun" into the immunogenic circle of life.

    GLTAL

    Sentiment: Strong Buy

  • Reply to

    I have many questions re: today's PR

    by alexp1112 Dec 18, 2014 9:23 AM
    rehdvm2004 rehdvm2004 Dec 18, 2014 10:48 AM Flag

    1. Historic controls and biopsy histopathology.
    2. No or little effect with no toxicity.
    3. Timing for vaccination is weekly, biweekly or monthly depending upon how quickly the immune system responds to the vaccination.
    4. Probably at least three, or more if no toxicity is observed.
    5. It is probably a compassionate IND that went through the UPenn IRB (Human Investigation Review Board). Academic medical centers can perform these studies as long as the protocol does not go over a state line and stays at the approving institution (UPenn affiliated medical centers in Pennsylvania would also qualify).
    6. Whenever you use an acronym, you have to spell it out first. BP = British Petroleum?

    Hope some of the above helps.

    GLTAL

    Sentiment: Strong Buy

  • rehdvm2004 rehdvm2004 Dec 18, 2014 10:10 AM Flag

    There is no doubt that controlling the interleukins and other cytokine responses is going to be a major factor in human medicine in the future. Some of it may trickle down to veterinary medicine depending on refining methods of administration. I worked with a scientist at the Center for Blood Research in Boston who could drop the serious clinical effects in animal models from 30% to 0% just by manipulating the cytokine responses. This will be a big factor in treating asthma by inhalation therapy in the future. You heard it here first.

    GLTAL

    Sentiment: Strong Buy

  • Reply to

    Standing Buy Order . . .

    by rehdvm2004 Dec 10, 2014 6:18 PM
    rehdvm2004 rehdvm2004 Dec 18, 2014 10:05 AM Flag

    Seems to have worked again yesterday. 500 at $7.35.

    GLTAL

    Sentiment: Strong Buy

  • Seems that there are several approved drugs that cause stem cells in the bone marrow to increase, release stem cells from the bone marrow and attract stem cells to a site of bodily injury. Again, these drugs are approved by the FDA. What is not understood is . . . that if you use these drugs in a particular sequence . . . you can get the body to heal itself at the site of injury. Healing without surgery. Guess what the basis of this research is !?! Lizards growing new tails which have skin, bone, muscle and nerves.

    93% of the American people are scientifically illiterate (illiterate means are smart but do not inform themselves). Modern molecular medicine is going to rewrite the methods of intervening, correcting and effecting cures of conditions that have plagued humans and animals for years. Be careful what you wish for . . . you may beat Methuselah's age record and have no SS left!

    ONCS IL12 has a place as the first generation T-cell cytokine. \

    GLTAL

    Sentiment: Strong Buy

  • rehdvm2004 by rehdvm2004 Dec 17, 2014 11:17 AM Flag

    This meeting is the key to more formulations using the liposome. Just add FDA to the key numbers and words in the title and the Guidelines to Industry pop right up. Like I said a long time ago and inquired from WL . . . the liposome that gets taken up by fixed macrophages in the lungs was the important discovery. That came out from Wedbrush (sp?) over the precancerous lesions in the rat lungs.

    GLTAL

    Sentiment: Strong Buy

  • rehdvm2004 rehdvm2004 Dec 17, 2014 10:22 AM Flag

    They are valuable for another reason which will surface in the next 5 years in human and veterinary medicine. Thanks for the tip.

    ONCS strong suit is elevating T-cell responses. This combines will with lots of different immunogenic/ immune modulation therapies. Stay tuned.

    GLTAL

    Sentiment: Strong Buy

  • Reply to

    Inquired with Saskatoon

    by rehdvm2004 Dec 13, 2014 9:58 AM
    rehdvm2004 rehdvm2004 Dec 17, 2014 10:18 AM Flag

    Thinking of telephoning them. That type of communication is off the record by modern legal terms. E-mails are an audit trail.

    Sentiment: Strong Buy

  • Reply to

    Buy and tuck away

    by indianboy238 Dec 17, 2014 9:15 AM
    rehdvm2004 rehdvm2004 Dec 17, 2014 9:40 AM Flag

    Think. What other immunological treatments would benefit from an increase in T-cells at a vaccination site? Also by different methods of administration like inhalation, for instance. The entire concept of medical treatments is being modified on a day-by-day basis by minimally invasive surgery, focal and intra-lesion treatments, enhancing mobilization of endogenous stem cells, cytokines, etc. Molecular medicine has changes the landscape for the future. Pick you spot, invest and wait. Follow the clinical and regulatory milestones but if any company keeps on track . . . eventually there will be a payday.

    GLTAL

    Sentiment: Strong Buy

  • Reply to

    Standing Buy Order . . .

    by rehdvm2004 Dec 10, 2014 6:18 PM
    rehdvm2004 rehdvm2004 Dec 17, 2014 8:53 AM Flag

    Picked up 500 shares at $7.40. Took two weeks. Updating the SPO.

    GLTAL

    Sentiment: Strong Buy

  • rehdvm2004 rehdvm2004 Dec 15, 2014 4:36 PM Flag

    You need to understand that for cancer, there are NO stand alone drugs. Cancer is a conglomerate of mutated cell clones with different sensitivities to different anticancer agents. Keytruda makes the cancer cell present different immunogenic components to the blood stream where T-lymphocytes attack the cancer as "foreign" to the body. An immune response. For many patients, they are immune suppressed and do not have an overwhelming T-cell response. IL12 causes an elevated/exaggerated T-cell response at a local site (where it is administered by electroporation). Hence, when the site is the cancer itself, there is an elevated combined immune response because of the additive effect of the two drugs. DiGrigorio figured this out back in the early 1970 and most cancer treatment protocols are a combination of drugs called "multiple modality therapy."

    GLTAL

    Sentiment: Strong Buy

  • Reply to

    Dr, Pierce

    by cameron12x Dec 9, 2014 9:43 PM
    rehdvm2004 rehdvm2004 Dec 15, 2014 8:29 AM Flag

    Investors are always over anxious about biopharma companies. They do not understand the regulatory pathway to get to milestones, or the fact that there are four basic milestones . . . Phase I, Phase IIa/IIb, Phase III and filing the completed NDA, BLA, NADA, DEA, etc.

    The value of ONCS is they have completed a Phase IIa/IIb and are now looking to collaborate in a Phase III. This can be done at UCSF or Hutchinson if both comprehensive cancer centers file with their respective IRBs to do a two modality cancer trial. One component will be to give IL12 and increase T-cell penetration into the tumors and the other will be administration of PD-1 which will unmask the cancer cells and present more surface antigens to T-cells and get a better response. If you think about it, the PD-1 is dependent upon the bodies own T-cell response for efficacy. Why not optimize T-cell response in the first place with IL12? That is the story as far as the science. How it plays out will be the dosing and repeat dosing of the two agents. But ONCS having the potential to file for a Phase III is important. No mistake about that.

    GLTAL

  • Reply to

    Standing Buy Order . . .

    by rehdvm2004 Dec 10, 2014 6:18 PM
    rehdvm2004 rehdvm2004 Dec 14, 2014 5:17 PM Flag

    The people who care about this company are the ones that have major lung infections . . . your focus on stock manipulation versus treatment of patients with lung infections . . . characterizes the lack of realistic appreciation for the science. It is the difference between long term appreciation of what the science and medicine might provide versus short term profits.

    If the advance of science and medicine was totally motivated by the mentality in this post . . . many of us would represent the "ultimate statistic" . . . "one life . . . one death."

    Just to clarify the difference . . . investors "care about this company because if they achieve their clinical and regulatory goals they will save lives."

    GLTAL

    Sentiment: Strong Buy

  • rehdvm2004 by rehdvm2004 Dec 13, 2014 9:58 AM Flag

    For as little or as much as it may be worth, I asked the Saskatchewan Government in Saskatoon if they could comment on the territorial Environmental Impact Study any time soon. Usually there is a regulatory clock that starts with submission and they can verify submission and an end review date. It is standard with regulatory agencies. We shall see.

    GLTAL

    Sentiment: Strong Buy

  • Reply to

    Standing Buy Order . . .

    by rehdvm2004 Dec 10, 2014 6:18 PM
    rehdvm2004 rehdvm2004 Dec 13, 2014 9:28 AM Flag

    You need to be patient with this Phase III. This type of study (255 enrollees) does not happen over night. I invested with the "forward look" of five years about 16 months ago. Drug development is one of the most heavily regulated and ponderously slow industries in the world.

    GLTAL

    Sentiment: Strong Buy

  • Reply to

    Hepatitis B Thread - WHO data

    by rehdvm2004 Dec 13, 2014 8:17 AM
    rehdvm2004 rehdvm2004 Dec 13, 2014 8:39 AM Flag

    Anyone can get a Hepatitis B Vaccination from CVS for $139.

    This is why pumping is just as bad as bashing.

    GLTAL

    Sentiment: Strong Buy

  • The following is a direct quote from the World Health Organization about the incidence and effects of Hep B.

    The incidence is high, but there is already a vaccine. Read on.

    "Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. It is a major global health problem. It can cause chronic liver disease and chronic infection and puts people at high risk of death from cirrhosis of the liver and liver cancer.

    More than 240 million people have chronic (long-term) liver infections. More than
    780 000 people die every year due to the acute or chronic consequences of hepatitis B.

    A vaccine against hepatitis B has been available since 1982. Hepatitis B vaccine is 95% effective in preventing infection and its chronic consequences, and was the first vaccine against a major human cancer."

    A new, therapeutic Hep B vaccine would be an improvement. Remember the DNA vaccines transmit to the liver more effectively than systemic antibody (for neutralizing antibody production) and the liver is the seat of the chronic infection. Same for Hep C, BTW.

    But the market estimate with the other thread is preposterous. Look up Hepatitis Vaccine sales to get a number.

    GLTAL

    Sentiment: Strong Buy

INSM
15.29+0.15(+0.99%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Novo Nordisk A/S
NYSEWed, Dec 24, 2014 2:48 PM EST